What ENSEM Therapeutics does

ENSEM Therapeutics is a clinical-stage biotechnology company founded in 2021 and incubated by CBC Group, focused on developing small molecule precision medicines for high-value and difficult-to-drug oncology targets. The company is headquartered in Waltham, Massachusetts, with an additional operational site in Shanghai, China, and operates with 11-50 employees. Its lead clinical programs address PI3Kα mutations, pan-KRAS, WRN (MSI-H cancers), and CDK2, with the latter licensed to BeiGene in a deal valued at up to $1.33 billion in milestones and royalties.

The company's core technology is the Kinetic Ensemble® platform, an AI-native drug discovery system that integrates molecular simulation, deep learning (EnsemNET™ for cryptic pocket prediction and EnsemGEN™ for generative ligand design), and advanced experimental validation to identify non-obvious cryptic binding pockets on traditionally undruggable protein targets. The pipeline consists of ETX-636 (allosteric pan-mutant-selective PI3Kα inhibitor and degrader in global Phase 1/2 with FDA Fast Track Designation in advanced breast cancer), ETX-929 (oral pan-KRAS inhibitor), ETX-880 (oral WRN inhibitor for MSI-H cancers), and ETX-197/BG-68501 (oral CDK2 inhibitor licensed to BeiGene).

ENSEM operates a hybrid business model: advancing wholly-owned pipeline assets through clinical development toward potential commercialization while generating near-term capital via licensing transactions with larger pharmaceutical partners. Revenue streams take the form of upfront payments, development, regulatory, and commercial milestone payments, and tiered royalties, as exemplified by the November 2023 BeiGene transaction. The company is privately held and has raised approximately $77 million cumulatively across a $67 million Series A2 (April 2022, led by GGV Capital) and a $10 million Series A+ (October 2023). Its customer base is concentrated in biopharmaceutical licensing partners and clinical trial sites rather than commercial product purchasers, as no products have been commercialized.

Name

ENSEM Therapeutics

Legal name

Ensem Therapeutics Inc.

Website

https://ensemtx.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

ENSEM Therapeutics is a clinical-stage biotechnology company using its AI-native Kinetic Ensemble® platform to discover cryptic binding pockets and develop small molecule precision medicines for difficult-to-drug oncology targets including PI3Kα, pan-KRAS, WRN, and CDK2.

Ownership category

akta.pro rank

Product category

Precision Oncology Pharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)

Keywords

• Oncology drug discovery
• Small molecule therapeutics
• Precision oncology medicines
• AI-driven drug design
• Cryptic pocket targeting

Headquarters

HQ city

Medford

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Licensing and Milestone Payments: ENSEM generates revenue through licensing its drug candidates to larger pharmaceutical companies, receiving upfront payments plus development, regulatory, and commercial milestone payments, and tiered royalties on net sales. Example: $1.33 billion deal with BeiGene for CDK2 inhibitor including upfront and milestone payments.
2. Drug Development and Commercialization: The company is advancing its own pipeline of small molecule precision medicines through clinical development with the goal of commercializing differentiated oncology drugs. ETX-636 is in Phase 1/2 clinical trials.

Go-to-market motion2 records

Marketing channels3 records

Core offering

ENSEM Therapeutics develops small molecule precision medicines for high-value and difficult-to-drug oncology targets using its proprietary Kinetic Ensemble® AI-driven drug discovery platform. The platform integrates computational modeling, AI deep learning, and advanced experimental validation to discover cryptic (non-obvious) binding pockets on proteins traditionally considered undruggable. The company advances an internal pipeline of precision oncology drug candidates and licenses select programs to larger pharmaceutical partners for development and commercialization.

Product overview

ENSEM Therapeutics is a biotechnology company that leverages its Kinetic Ensemble® platform to develop innovative small molecule precision medicines for oncology. The platform integrates computational and AI deep learning methodologies (including EnsemNET™ for cryptic pocket prediction and EnsemGEN™ for generative ligand design) with advanced experimental techniques. The company's pipeline includes four core drug candidates: ETX-636 (PI3Kα inhibitor in Phase 1/2), ETX-929 (pan-KRAS inhibitor), ETX-880 (WRN inhibitor), and ETX-197/BG-68501 (CDK2 inhibitor partnered with BeiGene).

Differentiator

Problem solved

Functional benefit

Products and services

• ETX-636 First-in-class allosteric pan-mutant-selective PI3Kα inhibitor and degrader for the treatment of advanced solid tumors harboring PI3Kα mutations, including HR+/HER2- breast cancer. Currently in global Phase 1/2 clinical trial with no hyperglycemia or dose-limiting toxicities observed in the U.S. arm.
• ETX-929 Potent, oral, potential best-in-class pan-KRAS inhibitor that spares HRAS and NRAS, demonstrating potent dual GTP (on) / GDP (off) state inhibitory activity for the treatment of diverse KRAS-mutant tumors.
• ETX-880 Oral, potent, and selective covalent inhibitor of Werner helicase (WRN) for the treatment of MSI-H cancers, including colorectal, gastric, and endometrial cancers.
• ETX-197 (BG-68501) Potential best-in-class oral CDK2 inhibitor for the treatment of patients with tumors that have cyclin E amplification and patients with acquired resistance to standard of care. Licensed globally to BeiGene in a deal valued at up to $1.33 billion plus tiered royalties.

Quantifiable outcome

• ETX-636 shows no hyperglycemia or dose-limiting toxicities in US arm of Phase 1/2 trial
• +2 more outcomes

Named customers2 records

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature4 records

Partnerships

One partnership is on record.

• BeiGenecoreStrategic or Co-development Partner · 21 November 2023BeiGene acquired an exclusive global license to ENSEM's IND-ready oral CDK2 inhibitor (ETX-197). ENSEM received upfront payment and is eligible for up to $1.33 billion in additional payments upon achievement of development, regulatory, and commercial milestones, plus tiered royalties. The partnership validates ENSEM's drug discovery capabilities.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Schrödinger: A computational chemistry and AI-driven drug discovery platform company. Schrödinger is a direct peer because both companies leverage physics-based simulation combined with ML to enable structure-based drug design on challenging targets—Schrödinger through its Living Chemistry Platform, ENSEM through Kinetic Ensemble.
• Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with ML to advance a pipeline of small molecule therapeutics. Recursion is a direct peer in AI-enabled small molecule drug discovery, with comparable pipeline breadth and a similar partnership-and-internal-pipeline dual business model.
• Iambic Therapeutics: AI-driven small molecule drug discovery company combining physics-based modeling with deep learning. Iambic is a direct peer given its overlapping focus on AI-designed small molecules for oncology and other targets, comparable platform-plus-pipeline model, and similar Series-stage scale.
• Insitro: Machine-learning-driven drug discovery company combining high-throughput biology with predictive models. Insitro is a direct peer as a clinical-stage AI drug discovery company pursuing novel small molecules with pharma partnerships (e.g., with Lilly and BMS).
• Exscientia: AI-driven precision medicine company with end-to-end drug discovery capabilities, including generative AI for molecule design and active clinical programs. Exscientia is a direct peer given its focus on AI-designed small molecules, oncology pipeline, and pharma partnership model.
• Relay Therapeutics: Precision medicine company using motion-based structural biology and AI to discover drugs against previously undruggable targets (e.g., PI3Kα, KRAS). Relay is a highly comparable direct peer because its Dynamo™ platform pursues the same target classes as ENSEM's Kinetic Ensemble and shares the focus on cryptic pockets and protein dynamics.
• XtalPi: AI-driven drug discovery company combining physics, quantum mechanics, and ML to accelerate small molecule design, with deep China-US operational footprint. XtalPi is a direct peer given comparable AI platform approach and similar geographic positioning relative to ENSEM's US-China operations.
• Atomwise: AI-driven small molecule drug discovery company using convolutional neural networks for structure-based design and hit identification. Atomwise is a direct peer given its focus on ML-enabled hit-to-lead optimization and established pharma partnership business model.

Emerging players

• Isomorphic Labs: Alphabet/DeepMind-affiliated drug discovery company applying AlphaFold-based structural biology and AI to therapeutic discovery. Isomorphic is an emerging player that could be both a competitor and a potential partner for ENSEM given its focus on protein structure prediction—an area central to ENSEM's cryptic-pocket discovery thesis.
• Generate Biomedicines: AI-driven generative biology company developing both biologics and small molecules. Generate is an emerging player with partial overlap to ENSEM via generative AI for protein dynamics-informed molecule design, though it focuses more on biologics than ENSEM's small molecule emphasis.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/ensemtx

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Funding overview

Funding rounds2 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ENSEM Therapeutics